Evan Seigerman
Evan Seigerman is a biopharma specialist at BMO, known for his insights into the pharmaceutical sector. Recently, he revised the revenue forecast for Merck's Gardasil vaccine due to declining demand, highlighting the challenges that the company faces in regaining investor trust amid market fluctuations.
Not in the pool (under ¢1).
Recent news mentions
Evan Seigerman, managing director and head of healthcare research at BMO Capital Markets in New York, commented on the growing market for weight-loss and diabetes drugs.
Canada will be a launching pad for the global race for generic Ozempic
Canada· 2026-01-30
Evan Seigerman, a financial analyst, anticipates that doctors and patients may turn to pills for weight maintenance.
Wegovy pill: With FDA approval, new era of oral GLP-1 weight loss drugs begins
United States· 2025-12-23
Evan Seigerman sought to assuage investor fears of coming price cuts in a research note.
Trump’s $150 Ozempic? Oz cautions it’s not a done deal, but patients and doctors say it could be a gamechangerUnited States· 2025-10-17
Evan Seigerman illustrated the importance of real-world usage for such medications.
Na trg vstopa tableta za hujšanje, ki naj bi postala vodilna na trgu
Slovenia· 2025-08-25
Evan Seigerman, senior biopharma analyst at BMO Capital Markets, commented on pharmaceutical companies' commitments.
Drugmakers are pouring billions of dollars into new US manufacturing. It still won’t achieve all of Trump’s tariff goalsUnited States· 2025-08-02
Analyst Evan Seigerman from BMO Capital Markets believes Eli Lilly, as an American company, better understood the nuances of the US market.
У «Оземпика» появился серьезный конкурент. Американцы уже чаще покупают именно этот препарат для похудения
Belarus· 2025-07-31
Evan Seigerman, analyst at BMO Capital Markets, noted that implementing something like this is pretty challenging.
Trump executive order demands pharma industry price cuts
Guyana· 2025-05-13
Evan Seigerman, analyst at BMO Capital Markets, mentioned that implementing something like this is pretty challenging.
Trump signs executive order to demand pharma industry cuts pricesGuyana· 2025-05-12Evan Seigerman, a BMO Capital Markets analyst, commented on the tolerable profile of orforglipron.
Trial shows Eli Lilly weight-loss pill works as well as Ozempic, shares surge in responseCanada· 2025-04-17
Evan Seigerman, a pharmaceuticals analyst with BMO Capital Markets, wrote that the industry is not expected to make any major changes.
New US tariffs could make it harder to get certain generic drugsUnited States· 2025-04-16
Evan Seigerman, a pharmaceuticals analyst with financial firm BMO Capital Markets, expressed skepticism about the effectiveness of tariffs in bringing drug manufacturing back to the US.
Trump drug tariffs would drive up prices, worsen shortages before any boost to US manufacturing, experts warnUnited States· 2025-04-09
Evan Seigerman, a biopharma specialist at BMO, reduced the revenue forecast for Gardasil this year by 13%.
Aktien des US-Pharmariesen sind ein Fall für Schnäppchenjäger
Switzerland· 2025-03-05
